ReviewOcular immunology and inflammation2012
Genetics of primary intraocular tumors.
Review in Ocular immunology and inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Global trends and emerging insights in ocular tumor-associated metabolites: a bibliometric and visualization analysis.Frontiers in molecular biosciences · 2025Article
- Non-Coding RNAs: Novel Regulators of Macrophage Homeostasis in Ocular Vascular Diseases.Biomolecules · 2024Review
- Review
- Susceptible to dynamism, immune to stagnancy - Martine Johanna Jager.Indian journal of ophthalmology · 2023Article
- Exploring the FGF/FGFR System in Ocular Tumors: New Insights and Perspectives.International journal of molecular sciences · 2022Review
- Molecular characteristics of uveal melanoma and intraocular tumors.Oncology letters · 2021Review
- Vitreoretinal lymphomas misdiagnosed as uveitis: Lessons learned from a case series.Indian journal of ophthalmology · 2016Article
- Inhibitory effect of bufalin on retinoblastoma cells (HXO-RB44) via the independent mitochondrial and death receptor pathway.American journal of translational research · 2016Article
- Matrine inhibits the growth of retinoblastoma cells (SO-Rb50) by decreasing proliferation and inducing apoptosis in a mitochondrial pathway.Molecular biology reports · 2014Article
- Serum vascular endothelial growth factor in patients with nonmelanoma primary ocular malignancies: A possible potential biomarker of tumor progression and poor prognosis.Oman journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
Abstract
Primary intraocular neoplasms are tumors that originate within the eye. The most common malignant primary intraocular tumor in adults is uveal melanoma and the second is primary intraocular lymphoma or vitreoretinal (intraocular) lymphoma. The most common malignant intraocular tumor in children is retinoblastoma. Genetics plays a vital role in the diagnosis and detection of ocular tumors. In uveal melanoma, monosomy 3 is the most common genetic alteration and somatic mutations of BAP1, a tumor suppressor gene, have been reported in nearly 50% of primary uveal melanomas. The retinoblastoma gene RB1 is the prototype tumor suppressor gene-mutations in RB1 alleles lead to inactivated RB protein and the development of retinoblastoma. Immunoglobulin heavy chain (IgH) or T-cell receptor (TCR) gene rearrangement is observed in B-cell or T-cell primary vitreoretinal lymphoma, respectively. Other factors related to the genetics of these three common malignancies in the eye are discussed and reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.